MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALMS

ALMS

Alumis Inc.

$28.81
-1.24
 (-4.13%)
Exchange:  NASDAQ
Market Cap:  3.556B
Shares Outstanding:  7.498M
Delayed data
Calculate ALMS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Martin Babler
Full Time Employees:  223
Address: 
280 East Grand Avenue
South San Francisco
CA
94080
US
Website:  https://www.alumis.com
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue0024,050
Gross Profit0-3,15220,554
EBITDA-153,709-291,081-248,390
Operating Income-158,174-300,754-427,204
Net Income-154,993-294,233-243,325

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets89,612340,992411,940
Total Liabilities53,50280,889110,643
Total Stockholders Equity36,110260,103301,297
Total Debt32,58030,72236,914
Cash and Cash Equivalents45,996169,52689,670

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-129,975-255,078-369,523
Capital Expenditure-4,499-1,732-653
Free Cash Flow-134,474-256,810-370,176
Net Income-154,993-294,233-243,325
Net Change in Cash20,293123,499-79,579

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)257,069.353Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,609,957.631Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)875,794.500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)128,534.676Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)804,978.815Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)437,897.250Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)88,549.850Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,268,207.737Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,085,386.145Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)438,263.163Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)2,744,726.727Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,493,093.064Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.280Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)2.670Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.100Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)3Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
421.04
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-15.01
?Enterprise Value
 (TTM)
: 
3.509B  ?EV/FCF
 (TTM)
: 
-9.31
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-54.63%  ?ROIC
 (TTM)
: 
-71.89%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.06
?P/B
 (TTM)
: 
6.32  ?Current Ratio
 (TTM)
: 
7.51

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ALMS valuation

Is Alumis Inc. (ALMS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Alumis Inc. (ALMS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ALMS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALMS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ALMS’s P/E ratio?

You can see ALMS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ALMS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ALMS a good long-term investment?

Whether ALMS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ALMS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.13
MARKETSnap

Trading Metrics:

Open: 29.56   Previous Close: 30.05
Day Low: 28.28   Day High: 29.6
Year Low: 3.33   Year High: 31.35
Price Avg 50: 24.23   Price Avg 200: 19.03
Volume: 790545   Average Volume: 1.349M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
25-06-2026 17:58
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
25-03-2026 12:39
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
19-03-2026 16:05
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read